B2

6 (Twice-amended). The pharmaceutical composition according to Claim 3 wherein the human growth factor is bFGF or VEGF.

Please add new claims 10-25 as follows:

B3

10 (New). The pharmaceutical composition according to Claim 4 wherein the human growth factor is bFGF or VEGF.

11 (New). A method of promoting angiogenesis in a patient in need thereof, comprising administering Component B and a human growth factor to the patient for a time sufficient and in an amount effective for the promotion of angiogenesis in the patient.

12 (New). The method of Claim 11, wherein the angiogenesis is in relation to the treatment of a wound, ulcer or other traumatic lesion to the tissues of the body of the patient.

13 (New). The method of claim 11, wherein the Component B and the human growth factor are administered in a single composition.

14 (New). The method of claim 12, wherein the Component B and the human growth factor are administered in a single composition.

15 (New). The method of claim 11, wherein the Component B and the human growth factor are administered in separate compositions.

16 (New). The method of claim 12, wherein the Component B and the human growth factor are administered in separate compositions.

17 (New). The method of claim 11, wherein the human growth factor is bFGF or VEGF.

18 (New). The method of claim 12, wherein the human growth factor is bFGF or VEGF.

19 (New). The method of claim 11, wherein the relative amounts of Component B and the human growth factor are selected to provide synergistic angiogenesis results.

20 (New). A method of treating a wound, ulcer or other traumatic lesion in a patient in need thereof, comprising administering Component B and a human growth factor to the patient for a time sufficient and in an amount effective for the treatment of the wound, ulcer or other traumatic lesion in the patient.

21 (New). The method of claim 20, wherein the Component B and the human growth factor are administered in separate administration doses.

22 (New). The method of claim 20, wherein the human growth factor is bFGF or VEGF.

23. (New). The method of claim 20, wherein the relative amounts of Component B and the human growth factor are selected to provide synergistic results.

24 (New). A pharmaceutical composition for use in the promotion of angiogenesis, comprising Component B and a human growth factor as active principles in combination with a pharmaceutically acceptable carrier, wherein the relative amounts of Component B and the human growth factor are selected to provide synergistic angiogenesis results when administered to a patient in need thereof.

25 (New). A pharmaceutical composition for use in the treatment of a wound, ulcer or other traumatic lesion, comprising Component B and a human growth factor as active principles in combination with a pharmaceutically acceptable carrier, wherein the relative amounts of Component B and the human growth factor are selected to provide synergistic results when administered to a patient in need thereof.

REMARKS

Claims 3-4, 6, and 10-25 presently appear in this case. No claims have been allowed. The official action dated October 1, 2002, has now been carefully considered. Reconsideration and allowance are hereby respectfully urged.

Briefly, the present invention relates to the use of Compound B combined with human growth factors in promoting angiogenesis. Such a combination can be used as cicatrizants to treat wounds, ulcers and other traumatic lesions. The